Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.

ABSTRACT:

Importance

Single-fraction preoperative ablative stereotactic partial breast irradiation (sPBI) can be safely delivered in early-stage hormone receptor-positive (HR+) breast cancer with delayed time to surgery and high pathologic complete response rates.

Objectives

To examine the maximum tolerated dose (MTD) of sPBI and to evaluate clinical outcomes, including pathological complete response (pCR), time to surgery, and toxic effects, associated with dose escalation.

Design, setting, and participants

This phase 1 nonrandomized clinical trial of dose escalation enrolled patients with HR+, ERBB2-negative, cN0 invasive breast cancer not requiring chemotherapy from a single academic center between December 2019 and April 2024.

Interventions

Patients were treated with

SUBMITTER: Rahimi A 

PROVIDER: S-EPMC12619099 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature